Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

Published:2019-01-01 Issue:1 Volume:24 Page:337-348
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Gökbuget Nicola¹,Dombret Hervé²,Giebel Sebastian³,Bruggemann Monika⁴,Doubek Michael⁵^ORCID,Foà Robin⁶,Hoelzer Dieter¹,Kim Christopher⁷,Martinelli Giovanni⁸,Parovichnikova Elena⁹^ORCID,Rambaldi Alessandro¹⁰,Ribera Josep-Maria¹¹^ORCID,Schoonen Marieke¹²,Stieglmaier Julia M.¹³,Zugmaier Gerhard¹³,Bassan Renato¹⁴

Affiliation:

1. Department of Medicine II, Department of Hematology/Oncology, University Hospital, Frankfurt, Germany

2. Hôpital Saint-Louis, University Paris Diderot, Paris, France

3. Maria Sklodowska Curie Memorial Cancer Center, Gliwice, Poland

4. Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

5. Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic

6. “Sapienza” University of Rome, Rome, Italy

7. Amgen Inc, Thousand Oaks, CA, USA

8. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

9. National Research Center for Hematology, Moscow, Russia

10. Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII, Bergamo, Italy

11. ICO-Hospital Germans Trias I Pujol, Josep Carreras Research Institute, Barcelona, Spain

12. Amgen Ltd, London, UK

13. Amgen GmBH, Munich, Germany

14. Ospedale dell’Angelo, Mestre-Venezia, Italy

Funder

Amgen

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2019.1567654

Reference34 articles.

1. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

2. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

3. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

4. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

5. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Need for consensus on primary end points and efficacy definitions in trials for adult acute lymphoblastic leukemia;Blood Advances;2024-08-13

2. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

3. How I treat newly diagnosed acute lymphoblastic leukemia;Clinical Hematology International;2024-05-09

4. Impact of a complex health services intervention in long-term care nursing homes on 3-year overall survival: results from the CoCare study;BMC Health Services Research;2024-02-14

5. Recommendations for the treatment and management of adult B‐Cell acute lymphoblastic leukemia in Asia‐Pacific: Outcomes from a pilot initiative;Asia-Pacific Journal of Clinical Oncology;2023-12-26